[Treatment strategy for HIV/AIDS including guidelines].
The introduction of highly active antiretroviral therapy (HAART) dramatically reduced HIV-associated morbidity and mortality. However HIV-associated metabolic syndrome, characterized by dyslipidemia and fat redistribution, is frequently observed in patients with HIV. Also an increase in the incidence of chronic kidney diseases(CKD) and non-AIDS indicated malignancies has been reported. When to start and what to start of HAART is important to improve and preserve immune function. A potential secondary benefit is protecting the complications after long-term therapy.